Indication |
For the treatment of ringworm infections of the skin, hair, and
nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae,
cradle cap or other conditions caused by Trichophyton or Microsporum fungi. |
Pharmacodynamics |
Griseofulvin is a mycotoxic metabolic product of Penicillium spp.
It was the first available oral agent for the treatment of
dermatophytoses and has now been used for more than forty years.
Griseofulvin is fungistatic with in vitro activity against various
species of Microsporum Epidermophyton, and Trichophyton. It has no
effect on bacteria or on other genera of fungi. Following oral
administration, griseofulvin is deposited in the keratin precursor cells
and has a greater affinity for diseased tissue. The drug is tightly
bound to the new keratin which becomes highly resistant to fungal
invasions. Once the keratin-Griseofulvin complex reaches the skin site
of action, it binds to fungal microtubules (tubulin) thus altering
fungal mitosis. |
Mechanism of action |
Griseofulvin is fungistatic, however the exact mechanism by which
it inhibits the growth of dermatophytes is not clear. It is thought to
inhibit fungal cell mitosis and nuclear acid synthesis. It also binds to
and interferes with the function of spindle and cytoplasmic
microtubules by binding to alpha and beta tubulin. It binds to keratin
in human cells, then once it reaches the fungal site of action, it binds
to fungal microtubes thus altering the fungal process of mitosis. |
Absorption |
Poorly absorbed from GI ranging from 25 to 70% of an oral dose.
Absorption is significantly enhanced by administration with or after a
fatty meal. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Primarily hepatic with major metabolites being 6-methyl-griseofulvin and its glucuronide conjugate. |
Route of elimination |
Not Available |
Half life |
9-21 hours |
Clearance |
Not Available |
Toxicity |
Side effects are minor: headaches, gastrointestinal reactions and cutaneous eruptions |